Contingency-Discrimintation Training (CDT) for Problem Behavior

Phase-Based Progress Estimates
Children's Specialized Hospital-Rutgers University Center for Autism Research, Education, and Services, Somerset, NJ
Problem Behavior+3 More
CDT - Behavioral
< 18
All Sexes
What conditions do you have?

Study Summary

Although behavioral treatments for decreasing destructive behavior, such as differential reinforcement of alternative behavior (DRA), are effective in the clinic, problem behavior often returns when a caregiver does not give the child their way in the natural environment (e.g., caregiver is busy with an infant sibling). This form of treatment relapse is known as resurgence. The goal of the current study is to evaluate whether alternating sessions in which the child can have their way (i.e., "on" sessions) with sessions in which the child can not have their way (i.e., "off" sessions) helps to mitigate resurgence.

Eligible Conditions

  • Problem Behavior
  • Aggression
  • Self-Injury

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Problem Behavior

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 5 years

5 years
Number of participants with resurgence
Number of sessions to criterion
Rate of problem behavior during resurgence test

Trial Safety

Safety Progress

1 of 3

Other trials for Problem Behavior

Trial Design

2 Treatment Groups

1 of 2
Contingency-Discrimintation Training (CDT)
1 of 2
Active Control
Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: Contingency-Discrimintation Training (CDT) · No Placebo Group · N/A

Contingency-Discrimintation Training (CDT)
Experimental Group · 1 Intervention: CDT · Intervention Types: Behavioral
ActiveComparator Group · 1 Intervention: Control · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Trial Background

Prof. Brian D. Greer Ph.D., BCBA-D, Director of Severe Behavior Program / Assistant Director of RUCARES and CSH-RUCARES / Assistant Professor of Pediatrics
Principal Investigator
Rutgers, The State University of New Jersey
Closest Location: Children's Specialized Hospital-Rutgers University Center for Autism Research, Education, and Services · Somerset, NJ
N/AFirst Recorded Clinical Trial
1 TrialsResearching Problem Behavior
0 CompletedClinical Trials

Eligibility Criteria

Age < 18 · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a boy or girl from ages 3 to 17.
You have a problem behavior that occurs at least 10 times a day, despite previous treatment.
You are on a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.